| BioWorld

Teva’s Copaxone Failure In MS Attributed To Low Relapse Rate

Orchid Raises $23M Through Public Offering Of 8M Shares

Use Partners To Pack Pipeline But Not Too Early, Panel Says

NEW YORK - Partners matter. But products matter more, and the one can be used to reach the other, said Donald Drakeman, president and CEO of Medarex Inc., the transgenic mouse company with “about four dozen” collaborators. (BioWorld Today) Read More